Arax Advisory Partners
FHTX icon

Arax Advisory Partners’s Foghorn Therapeutics FHTX Stock Holding History

Arax Advisory Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54K Buy
+1,136
New +$5.04K ﹤0.01% 4565
2025
Q4 		– Sell
-519
Closed -$2.54K – 4236
2025
Q3 		$2.54K Buy
+519
New +$2.75K ﹤0.01% 3056

Other funds holding FHTX

Flagship Pioneering
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Arax Advisory Partners's FHTX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Foghorn Therapeutics (FHTX) in Q2 2026: 1,136 shares worth $5.54K. The stake represents ﹤0.01% of the portfolio and ranks #4565 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in FHTX as recently as Q3 2025.

Arax Advisory Partners first reported a position in FHTX in Q3 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Arax Advisory Partners held 1,136 shares of Foghorn Therapeutics worth $5.54K as of Q2 2026.
  • Foghorn Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Foghorn Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4565 holding.
  • Arax Advisory Partners first reported a position in Foghorn Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.